PO022 Metformin and Dapagliflozin Effects On Epicardial Adipose Tissue Area In Prediabetes and Type 2 Diabetes Patients: MRI Evaluation Studies

摘要: 397421) (n=56 patients ,mean age 67 ± 7 y; mean BMI 32.5± 5.3 kg/m2) with chronic heart failure and type 2 diabetes who received either dapagliflozin (10mg/day) or placebo for 12 months respectively. Results: Metformin treatment in the METREMODEL trial reduced body weight significantly by 4.2kgs (p=0.001).but did not reduce EAT area (metformin -0.1 3.8 cm2 vs. -0.5 2.9 p= 0.7). In REFORM trial, -1.9 kg (p= 0.054) no significant reduction (dapagliflozin -1.00 3.6 -0.7 3.1 p=0.8). Conclusion: In prediabetes diabetes, we found that metformin resulted loss but had effect on EAT. Our findings suggest reported cardiovascular benefits of these two diabetic therapies are likely to be mediated effects